Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients

Kidney International

Volumn 78, Issue SUPPL. 117, 2010, Pages

  Mittman, Neal ^a   Desiraju, Brinda ^a   Fazil, Irfan ^a   Kapupara, Hiteshkumar ^a   Chattopadhyay, Jyoti ^a   Jani, Chinu M ^b   Avram, Morrell M ^a  

^a LONG ISLAND COLLEGE HOSPITAL   (United States)

^b Spectra Laboratories   (United States)

Author keywords

diabetes; fructosamine; HbA1c; hemodialysis; hospitalization; infection

Indexed keywords

ALBUMIN; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; FOLLOW UP; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT MONITORING; PRIORITY JOURNAL; URBAN AREA; BLOOD; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; HEMODIALYSIS; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; STATISTICAL MODEL; UNITED STATES; URBAN POPULATION;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FRUCTOSAMINE; HEMODIALYSIS UNITS, HOSPITAL; HEMOGLOBIN A, GLYCOSYLATED; HOSPITALIZATION; HUMANS; INFECTION; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; NEW YORK; PROSPECTIVE STUDIES; RENAL DIALYSIS; URBAN POPULATION;

EID: 77955156159     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.193     Document Type: Article

References (24)

1. United States Renal Data System. USRDS 2007 Annual Data Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney disease, Bethesda, MD, 2007.
2. Oomichi T, Emoto M, Tabata T et al. Impact of glycemic control on survival of diabetic patients on chronic regular hemodialysis: a 7-year observational study. Diabetes Care 2006; 29: 1496-1500.
3. McMurray SD, Johnson G, Davis S et al. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. Am J Kidney Dis 2002; 40: 566-575.
4. Selvin E, Coresh J, Golden SH et al. Glycemic control and coronary heart disease risk in persons with and without diabetes. The atherosclerosis risk in communities study. Arch Intern Med 2005; 165: 1910-1916.
5. Levitan EB, Song Y, Ford ES et al. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? Arch Intern Med 2004; 164: 2147-2155.
6. Kalantar-Zadeh K, Kopple JD, Regidor DL et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007; 30: 1049-1055.
7. Coronel F, Marcia M, Ciodoncha A et al. Fructosamine levels in CAPD: its value as glycemic index. Adv Perit Dial 1991; 7: 253-256.
8. Inaba M, Okuno S, Kumeda Y et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007; 18: 896-903.
9. Peacock TP, Shihabi ZK, Bleyer AJ et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008; 7: 1062-1068.
10. Ichikawa H, Nagake Y, Takahashi M et al. What is the best index of glycemic control in patients with diabetes on hemodialysis? Nippon Jinzo Gakkai shi 1996; 38: 305-308.
11. Nunoi K, Kodama T, Sato Y et al. Comparison of reliability of plasma fructosamine and glycosylated hemoglobin assays for assessing glycemic control in diabetic patients on hemodialysis. Metabolism 1991; 40: 986-989.
12. Browner WS, Pressman AR, Lui L-Y et al. The association between serum fructosamine and mortality in elderly women. The study of osteoporotic fractures. Am J Epidemiol 1999; 149: 471-475.
13. Nakao T, Matsumoto H, Okada T et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 1998; 37: 826-830.
14. Shoji T, Tabata T, Nishizawa Y et al. Clinical availability of serum fructosamine measurement in diabetic patients with uremia. Use as a glycemic index in uremic diabetes. Nephron 1989; 51: 338-343.
15. Lamb E, Venton TR, Cattell WR et al. Serum glycated albumin and fructosamine in renal dialysis patients. Nephron 1993; 64: 82-88.
16. Joy MS, Cefalu WT, Hogan SL et al. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 2002; 39: 297-307.
17. Cohen G, Rudnicki M, Walter F et al. Glucose-modified proteins modulate essential functions and apoptosis of polymorphonuclear leukocytes. J Am Soc Nephrol 2001; 12: 1264-1271.
18. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 2008; 45: 1-16.
19. Dronge AS, Perkal MF, Kancir S et al. Long-term glycemic control and postoperative infectious complications. Arch Surg 2006; 141: 375-380.
20. Vijayan G, Sundaram RC, Bobby Z et al. Increased plasma malondialdehyde and fructosamine in anemic H. pylori infected patients: effect of treatment. World J Gastroenterol 2007; 13: 796-800.
21. Williams ME, Lacson Jr E, Teng M et al. Extremes of glycemic control (HbA1c) increase hospitalization risk in diabetic hemodialysis patients in the USA. Am J Nephrol 2009; 29: 54-61.
22. Yamada S, Inaba M, Shidara K et al. Association of glycated albumin, but not glycated hemoglobin, with peripheral vascular calcification in hemodialysis patients with type 2 diabetes. Life Sci 2008; 83: 516-519.
23. Van Dieijen-Visser MP, Seynaeve C, Brombacher PJ. Influence of variations in albumin or total-protein concentration on serum fructosamine concentration. Clin Chem 1986; 32: 1610.
24. United States Renal Data System. Excerpts from the USRDS 2008 annual data report: Atlas of end-stage renal disease in the United States. Am J Kidney Dis 2009; 53(Suppl 1): S129-S142